Dimension Therapeutics Expands Leadership Team, Names Eric Crombez, M.D., as Chief Medical Officer

- Stephanie Haller Appointed as Vice President, Clinical Operations -

- Dimension Advancing Proprietary Gene Therapy Programs toward Clinical Testing; First Trial Expected to Commence in Hemophilia B Patients in 2015 -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dimension Therapeutics, Inc. ("Dimension" or the "Company") a gene therapy company advancing novel treatments for hemophilia and rare diseases, today announced that Eric Crombez, M.D., former senior medical director, Global Clinical Development, at Shire plc, has been appointed to the newly created position of Chief Medical Officer. Dr. Crombez will lead Dimension's team advancing the company's development pipeline of novel gene therapy candidates into clinical testing. Dimension's lead, wholly owned program in hemophilia B is anticipated to enter clinical testing in 2015. Dr. Crombez will report directly to Dimension's CEO Annalisa Jenkins, MBBS, MRCP. In addition, Dimension today announced the appointment of Stephanie Haller, Shire's former director, Clinical Programs, Early Phase Development, to the newly created position of Vice President of Clinical Operations. The appointments of Dr. Crombez and Ms. Haller are effective immediately.

"We are delighted with the additions of Eric Crombez and Stephanie Haller at a time when the Company is preparing to initiate its first clinical study next year"
"We are delighted with the additions of Eric Crombez and Stephanie Haller at a time when the Company is preparing to initiate its first clinical study next year," commented Dr. Jenkins. "Very recently, Dimension celebrated its first anniversary, and we have been able to accomplish a great deal in a very short period of time – building our teams, signing a major agreement with a leading partner, Bayer, in hemophilia A, and attracting top-tier investors. Eric and Stephanie will play critical roles in the next phase of our development, and we are happy to welcome them to the team."

Dr. Crombez stated, "Gene therapy is coming of age, following the first product approval in Europe and the continued validation and clinical proof of concept for the new generation of novel AAV products now transforming the field. It's an exciting time for this area of medicine, holding great promise for families affected by rare genetic disorders. I speak for Stephanie as well in saying how thrilled we are to join the Dimension team, which we believe is well-positioned to unlock the potential of these new therapies and bring real benefits to patients."

Eric Crombez, M.D.

Dr. Crombez brings to Dimension extensive experience and expertise in the development and execution of clinical development programs for rare genetic disorders. While at Shire, Dr. Crombez served as medical director and then senior medical director of Global Clinical Development. He played a key role in the advancement of the pivotal trials and global marketing registration submissions for VPRIV™ (velaglucerase alfa for injection), Shire's enzyme replacement therapy for the treatment of Type 1 Gaucher disease which is now available in the US and more than 40 other countries. Dr. Crombez also played a key role in the translation of Shire's intrathecal enzyme replacement therapy program for Metachromatic Leukodystrophy from bench research into clinical trials. Previously, Dr. Crombez was assistant professor, Department of Pediatrics, Division of Medical Genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Dr. Crombez is a board-certified clinical geneticist and has authored more than 40 peer-reviewed articles, book chapter and presentation abstracts. Dr. Crombez obtained his B.S. degree in biology from the University of Michigan, Ann Arbor, and his M.D. degree from Wayne State University School of Medicine, Detroit. Dr. Crombez completed residencies in pediatrics and medical genetics and a fellowship in clinical biochemical genetics at the UCLA School of Medicine.

Stephanie Haller

Ms. Haller brings to Dimension broad experience in the design and successful management of large, global clinical trial programs. Most recently, she served as director of Clinical Programs, Device Team and Early Phase Development at Shire, responsible for the execution of global clinical development in rare genetic diseases. Previously, at Genzyme Corporation, Ms. Haller held clinical trial management roles of increasing responsibility, attaining the position of associate director, Clinical Research. Prior to this, she held clinical research positions at Muro Pharmaceuticals (part of Asta Medica Inc.) and ICON Clinical Research. Ms. Haller received her B.A. degree in psychology from Denison University and is a candidate for an M.S. degree in experimental psychology from Villanova University.

About Dimension Therapeutics

Dimension Therapeutics, Inc. is a gene therapy company focused on developing novel treatments for patients with hemophilia and rare diseases. Dimension has built a product development pipeline based on an industry-leading adeno-associated virus (AAV) platform, and the Company is advancing multiple gene therapy programs toward clinical development. These programs include a collaboration with Bayer HealthCare in hemophilia A and a wholly owned program in hemophilia B. Dimension has preferred access to multiple best-in-class AAV vectors from REGENXBIO. The Dimension team and senior advisors comprise biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. In June 2014 the company announced a Series A financing with participation by leading investors Fidelity Biosciences and OrbiMed. For more information, please visit www.dimensiontx.com.

Contacts

Burns McClellan, on behalf of Dimension Therapeutics
Justin Jackson, 212-213-0006, ext.327
[email protected]
 

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.